The J.P. Morgan Healthcare Conference is a premier healthcare investment symposium that connects global industry leaders, fast-growth start-up companies, innovative technology creators, and members of the investment community.
Key takeaways from the conference this year included:
- AI in Healthcare: AI continued to be the headline theme, with discussions on its potential to transform diagnosis and decision support, drug discovery and healthcare IT.
- Genomic Sequencing: Competition is heating up in the genomic sequencing market with newer entrants challenging established players like Illumina.
- Digital Health: Partnerships continue to emerge as a key strategy for digital health companies.
- Big Tech in Healthcare: Companies like Alphabet and Amazon are making significant moves in the healthcare sector.
“At the JP Morgan Healthcare Conference our team showcased its technology and AI based medical concepts to highly interested parties from government, investors and research partnerships.” said Dr. Aamer Ahmed, Senior Cardiac Anesthesiologist and Chief Medical Officer at Hemeo. “Our technology and Clinical Decision Software (CDS) solutions target a critical unmet need in the clinical environment. Health program leaders continue to see the value in our patient blood management solutions to offer better optimization of blood products in the operating theater. Clinicians see the benefits our technology can bring to help them manage complex coagulopathic problems during and after surgery.”
Hemeo’s leadership took part in multiple investor-based meetings during the JP Morgan Healthcare conference. Participation included attendance at the CSSi Life Sciences Partnering Forum, RESI 2025 @ JPM and the Non-Dilutive Funding Summit, sponsored by Free Mind. RESI is held concurrently with JP Morgan Healthcare Week and is the largest and most comprehensive healthcare investment symposium that week, attracting thousands of life science professionals globally.
With its proprietary technology addressing critical needs in cardiology, hematology, and patient blood management, Hemeo continues to attract strategic interest from investors and funding organizations focused on cutting-edge solutions.
“During this exciting week, we met with several potential investment partners and with the Program Director from the NIHs, National Heart, Lung and Blood institute about several potential opportunities for NIH based grants.,” said Lee DeGeer, Hemeo’s President, and CEO. “Each discussion was incredibly positive concerning Hemeo’s Technology and our soon to launch Vantage CDS SW product. It was clear that we fit into the sweet spot for what the NHLBI prefers to support and look forward to future opportunities to collaborate.”